GH Stock Cash Flow Statements

Guardant Health Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Guardant Health Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31

operating activities:
net income	-99,899,000	-95,159,000	-111,006,000	-107,754,000	-102,628,000	-114,985,000	-187,043,000	-86,102,000	-72,771,000	-133,533,000	-139,934,000	-161,994,000	-229,432,000	-123,228,000	-72,311,000	-107,526,000	-97,575,000	-107,358,000	-93,045,000	-71,670,000	-49,739,000	-31,829,000	-22,110,000	-13,090,000	-11,300,000	-21,351,000	-25,272,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	10,042,000	10,236,000	10,454,000	10,598,000	10,623,000	10,712,000	10,868,000	11,037,000	10,631,000	10,345,000	10,169,000	9,807,000	8,785,000	7,201,000	6,090,000	5,544,000	5,627,000	5,010,000	4,603,000	4,353,000	3,805,000	3,304,000	3,448,000	2,952,000	2,657,000	2,354,000	2,169,000
operating lease costs	8,572,000	7,870,000	7,776,000	8,131,000	7,607,000	7,619,000	7,553,000	7,438,000	7,369,000	7,339,000
gain on extinguishment of convertible notes	0	-13,672,000
stock-based compensation	42,462,000	37,757,000	36,366,000	49,769,000	27,235,000	27,041,000	24,320,000	21,819,000	22,354,000	22,266,000	23,703,000	20,639,000	25,544,000	24,799,000	26,857,000	35,016,000	34,507,000	55,069,000	56,762,000	55,198,000	25,815,000	6,338,000	5,072,000	5,485,000	3,215,000	3,182,000	2,563,000
unrealized losses on marketable equity securities											-5,437,000
impairment of non-marketable equity securities	0	5,000,000								5,485,000
interest income received on marketable debt securities	0	7,677,000
other	-1,220,000	940,000	-144,000	987,000	733,000	652,000	-1,286,000	6,000				3,000	-1,000	21,000
changes in operating assets and liabilities:
accounts receivable	-14,310,000	-6,115,000	-21,705,000	12,053,000	-15,957,000	4,220,000	18,000	-2,335,000	-1,654,000	12,349,000	-11,056,000	9,076,000	-10,944,000	13,299,000	-36,908,000	-7,077,000	-5,628,000	5,260,000	-17,044,000	4,687,000	7,073,000	-179,000	-8,297,000	674,000	-11,374,000	11,608,000	-21,050,000
inventory	-6,805,000	-6,173,000	1,214,000	-5,314,000	-3,993,000	-1,042,000	15,085,000	-16,504,000	-14,056,000	5,125,000	11,449,000	-3,157,000	-23,281,000	-5,937,000	-5,934,000	1,755,000	2,382,000	-6,160,000	5,015,000	-7,377,000	4,794,000	-9,967,000	-421,000	-584,000	-3,920,000	-1,120,000	-2,061,000
prepaid expenses and other current assets	-4,204,000	-3,072,000	1,501,000	-531,000	-3,034,000	-5,627,000	-1,774,000	-1,667,000	2,463,000	-3,354,000	-7,943,000	4,717,000	1,788,000	21,882,000	-29,995,000	-2,722,000	-3,557,000	521,000	-6,568,000	53,000	3,036,000	-2,598,000	-5,732,000	-1,575,000	2,069,000	-947,000	-1,180,000
other assets	388,000	697,000	-814,000	-1,431,000	-1,154,000	1,024,000	-982,000	580,000	-65,000	1,765,000	6,928,000	469,000	455,000	3,846,000	-956,000	1,056,000	-5,484,000	1,202,000	-11,755,000	-7,329,000	-403,000	161,000	-1,809,000	86,000	-296,000	-833,000	-548,000
accounts payable and accrued liabilities	-2,736,000	-1,537,000	16,993,000	-4,788,000	-28,265,000	13,240,000	62,014,000	10,065,000	2,626,000	13,886,000
operating lease liabilities	-9,261,000	-9,565,000	-9,086,000	-9,333,000	-8,861,000	-8,835,000	-8,754,000	-7,754,000	-7,548,000	-7,422,000	-7,235,000	-6,398,000	-3,489,000	-3,106,000	13,947,000	3,291,000	-271,000	-2,762,000	-2,519,000	358,000	-2,023,000	-1,858,000
deferred revenue	16,686,000	2,427,000	9,065,000	-2,855,000	7,566,000	4,887,000	-1,435,000	9,224,000	-1,911,000	-4,145,000	5,821,000	-1,897,000	6,706,000	-757,000	4,009,000	-1,163,000	120,000	-190,000	1,213,000	-4,148,000	-451,000	-341,000	-818,000	-3,401,000	-617,000	975,000	12,183,000
net cash from operating activities	-60,285,000	-62,689,000	-64,513,000	-51,059,000	-94,002,000	-30,284,000	-78,728,000	-77,791,000	-94,015,000	-74,441,000	-90,749,000	-78,160,000	-111,935,000	-28,619,000	-76,988,000	-53,145,000	-62,593,000	-16,291,000	-59,223,000	-8,057,000	-23,365,000	-13,282,000	-30,342,000	1,347,000	-13,836,000	-4,303,000	-26,538,000
capex	-5,649,000	-4,459,000	-18,875,000	0	-5,077,000	-5,294,000	-4,077,000	-2,372,000	-6,513,000	-7,524,000	-10,001,000	-21,726,000	-23,034,000	-22,700,000	-697,000	-22,849,000	-18,675,000	-9,586,000	0	-9,786,000	-9,507,000	-9,598,000	0	2,544,000	-3,047,000	-2,705,000	-2,931,000
free cash flows	-65,934,000	-67,148,000	-83,388,000	-51,059,000	-99,079,000	-35,578,000	-82,805,000	-80,163,000	-100,528,000	-81,965,000	-100,750,000	-99,886,000	-134,969,000	-51,319,000	-77,685,000	-75,994,000	-81,268,000	-25,877,000	-59,223,000	-17,843,000	-32,872,000	-22,880,000	-30,342,000	3,891,000	-16,883,000	-7,008,000	-29,469,000
investing activities:
maturities of marketable debt securities	0	307,323,000	0
purchases of non-marketable equity securities
purchases of property and equipment	-5,649,000	-4,459,000	-18,875,000													-22,149,000	-18,675,000	-9,586,000		-9,786,000	-9,507,000	-9,598,000
net cash from investing activities	-10,649,000	302,864,000	10,530,000	-294,827,000	-5,077,000	28,066,000	663,454,000	260,699,000	-241,127,000	157,224,000	70,627,000	41,274,000	-72,893,000	110,808,000	-266,697,000	-47,394,000	127,066,000	123,870,000	-297,685,000	-14,656,000	-325,549,000	20,804,000	23,358,000	-35,730,000	-320,527,000	15,329,000	-197,688,000
financing activities:
proceeds from issuance of common stock upon exercise of stock options	1,557,000	768,000	522,000	20,000	2,364,000	213,000	115,000	70,000	63,000	157,000	120,000	347,000	1,195,000	963,000	1,047,000	1,677,000	926,000	4,462,000	2,129,000	3,851,000	2,044,000	1,504,000	1,844,000	4,265,000	4,992,000	538,000	539,000
proceeds from issuances of common stock under employee stock purchase plan				0				0				0				0				0				3,185,000	0	1,933,000
employee taxes paid related to net share settlement of restricted stock units
repurchase of treasury stock	0	-45,010,000
payment of debt issuance costs	-151,000	-12,138,000
proceeds from unwinding of convertible note hedges	0	5,030,000
net cash from financing activities	1,624,000	-66,850,000	-2,935,000	-2,885,000	5,898,000	-1,074,000	90,568,000	3,807,000	383,854,000	-854,000	2,318,000	-19,312,000	-172,087,000	-12,000	3,780,000	-5,560,000	4,909,000	-69,953,000	1,046,724,000	797,000	361,320,000	1,466,000	3,077,000	6,871,000	355,068,000	2,288,000	250,364,000
net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	937,000	773,000	-1,695,000	1,900,000	-837,000	-1,138,000	1,030,000	-526,000	-1,252,000	-163,000	1,140,000	-529,000	-1,419,000	-792,000		-113,000	7,000	-1,087,000
net increase in cash, cash equivalents and restricted cash	-68,373,000	174,098,000	-58,613,000	-346,871,000	-94,018,000	-4,430,000	676,324,000	186,189,000	47,460,000	81,766,000	-16,664,000	-56,727,000	-358,334,000	81,385,000	-340,405,000	-106,212,000	69,389,000	36,539,000					-3,960,000	-27,465,000	20,864,000	13,245,000	26,165,000
cash, cash equivalents and restricted cash—beginning of period	0	629,755,000		0	0	1,133,687,000			0	141,948,000		0	0	492,288,000
cash, cash equivalents and restricted cash—end of period	-68,373,000	803,853,000		-346,871,000	-94,018,000	1,129,257,000			47,460,000	223,714,000		-56,727,000	-358,334,000	573,673,000		-106,212,000	69,389,000	869,516,000
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	-69,429,000	698,572,000	-59,482,000	-348,672,000	-95,333,000	1,029,027,000										-106,220,000
restricted cash	1,056,000	105,281,000
total cash, cash equivalents and restricted cash	-68,373,000	803,853,000	-58,613,000	-346,871,000	-94,018,000	1,129,257,000										-106,212,000
employee taxes paid related to settlement of restricted stock units		-15,497,000
contingent consideration							-120,000	220,000	310,000	-300,000
amortization of debt issuance costs			646,000	645,000	645,000	645,000	644,000	644,000	643,000	644,000		642,000	642,000	642,000		640,000	641,000	641,000
amortization of (discount) premium on marketable debt securities							-2,639,000	-7,828,000	-2,076,000	-1,009,000
unrealized and realized losses (gains) on marketable equity securities			-2,824,000
impairment of non-marketable equity securities and other related assets							0	0
fair value adjustments of noncontrolling interest liability											0	0
other legal liabilities
purchases of marketable debt securities			0
sales of marketable equity securities and other related assets
purchases of non-marketable equity securities and other related assets			-5,000,000
proceeds from issuance of common stock under employee stock purchase plan
proceeds from equity offerings
payment of equity offering costs
joint venture acquisition											0	0
tender offer issued in connection with the joint venture acquisition and acquisition related costs											1,000
cash, cash equivalents and restricted cash – beginning of period
cash, cash equivalents and restricted cash – end of period
supplemental disclosures of cash flow information:
cash paid for income taxes																							0			-48,000
supplemental disclosures of noncash investing and financing activities:
operating lease liabilities arising from obtaining right-of-use assets											0			3,940,000	314,000	157,000	64,000	170,847,000
purchases of property and equipment included in accounts payable and accrued liabilities
restricted cash – included in restricted cash
restricted cash – included in other assets																8,000
amortization of discount on marketable debt securities
cash effect of changes in operating assets and liabilities:
sales of marketable equity securities
taxes paid related to net share settlement of restricted stock units				-2,874,000	-3,240,000	-1,544,000	-3,085,000	-3,003,000	-4,116,000	-993,000	-1,359,000	-4,340,000	-1,222,000	-957,000	-1,602,000	-7,199,000	-1,382,000	-73,576,000	-1,200,000
proceeds from follow-on public offering								0
payment of offering costs related to follow-on public offering								793,000
restricted cash – included in cash, cash equivalents and restricted cash				1,801,000	1,315,000	100,230,000
amortization of premium (discount) on marketable debt securities					-4,000	111,000					1,229,000
unrealized losses (gains) on marketable equity securities					15,485,000	30,054,000
purchase of marketable debt securities							0	-68,563,000	-498,087,000	-63,252,000	-65,156,000
maturity of marketable debt securities					0	35,000,000	666,000,000	336,000,000	264,700,000	228,000,000	157,000,000
purchase of non-marketable equity securities and other related assets							0	-4,366,000
purchase of property and equipment					-5,077,000	-6,934,000	-4,077,000	-2,372,000	-6,513,000	-7,524,000	-10,001,000	-21,726,000	-23,034,000	-22,700,000											-3,047,000	-2,705,000	-2,931,000
purchase of property and equipment included in accounts payable and accrued liabilities						1,640,000
unrealized (gains) losses on marketable equity securities							4,803,000
reclassification of redeemable noncontrolling interest to noncontrolling interest liability
unrealized gains on marketable equity securities									-63,997,000	-3,882,000
payments made on finance lease obligations									-19,000	-18,000	-18,000	-18,000	-17,000	-18,000	-17,000	-38,000	-36,000	-55,000	-49,000
purchase of non-marketable equity securities and other related investments												0
non-cash operating lease costs											7,191,000	7,197,000	7,248,000	6,949,000	6,879,000	6,943,000	6,907,000	3,932,000	2,218,000
charge of in-process research and development costs with no alternative future use																			0	0	0	8,500,000
re-valuation of contingent consideration											110,000	390,000	1,415,000	2,390,000	535,000	970,000			0	70,000	0	-190,000
amortization of debt discount and debt issuance costs
impairment of other assets											0
credit loss adjustment and others															39,000				-905,000
purchase of intangible assets and capitalized license obligations																			0
payment of contingent consideration											0
proceeds from public offerings of common stock
payment of offering costs related to public offerings of common stock
proceeds from borrowings on convertible senior notes
payment of offering costs related to borrowings on convertible senior notes															0	0	0	-784,000
purchase of convertible note hedges
property and equipment acquired under finance leases															0	2,000
vesting of common stock exercised early
debt issuance costs included in accounts payable and accrued liabilities
accounts payable												6,663,000	11,842,000	-753,000	1,699,000	-173,000	-4,874,000	11,986,000	-8,705,000	3,322,000	-11,967,000	9,491,000	3,915,000	-2,987,000	6,023,000	-2,610,000	1,698,000
accrued compensation												18,751,000	-17,486,000	13,662,000	3,658,000	4,103,000	-2,445,000	8,900,000	4,243,000	5,511,000	-4,409,000	4,378,000	-6,047,000	10,917,000	-996,000	1,697,000	5,556,000
accrued expenses and other liabilities												-1,125,000	7,137,000	8,022,000		3,180,000	2,905,000	4,399,000		306,000				3,429,000
purchase of property and equipment included in accounts payable and accrued expenses
issuance costs related to purchase of non-marketable equity and other related investments included in accounts payable and accrued expenses																-241,000
amortization of premium (discount) on marketable securities													1,351,000	2,449,000	3,303,000	3,018,000	3,269,000	3,259,000	2,380,000	571,000	485,000	580,000
purchase of marketable securities													-74,859,000	-163,742,000											-372,875,000	-45,966,000	-238,757,000
maturity of marketable securities													25,000,000	310,000,000	325,000,000	209,000,000	214,000,000	204,110,000	255,000,000	110,000,000	93,500,000	104,048,000	102,269,000	93,904,000	65,160,000	64,000,000	44,000,000
purchase of non-marketable equity and other related investments														-12,750,000	-346,000	-26,326,000
unrealized translation gains on obligation related to royalty																								-279,000
benefit from income tax differences
changes in operating assets and liabilities, net of effect of acquisition:
accrued expenses and other current liabilities																										2,308,000	-255,000
business acquisition, net of cash acquired																							0
payment in connection with a license agreement
payments made on royalty obligations																								-77,000	-78,000	-73,000
net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash																							-53,000	47,000	159,000	-69,000
cash paid for interest																							321,000	280,000	287,000	293,000
purchases of property and equipment included in accounts payable and accrued expenses															-697,000	-700,000								2,544,000
initial fair value of contingent consideration at acquisition date																							0	-70,000
debt issuance costs included in accounts payable and accrued expenses
purchases of marketable securities																-207,919,000	-55,509,000	-70,654,000		-114,870,000	-409,542,000	-55,760,000
proceeds from public offering, net of underwriting discounts and commissions																				0
payment of offering costs related to public offering																				-761,000
cash and cash equivalents—beginning of period																0	0	832,977,000
follow-on public offering issuance costs included in accounts payable and accrued expenses
deferred rent																								397,000	1,937,000	1,131,000	221,000
proceeds from issuance of common stock upon the exercise of warrants																											7,000
repurchase of common stock																											0
net proceeds from issuance of equity interests in redeemable noncontrolling interest																											0
cash and cash equivalents – end of period
deferred offering costs included in accounts payable and accrued expenses
conversion of convertible preferred stock to common stock upon initial public offering
unrealized translation gains (loss) on obligation related to royalty
net effect of foreign exchange rate changes on cash and cash equivalents																				190,000	26,000	23,000
amortization of right-of-use assets																					1,890,000	1,496,000
others																					-75,000	56,000
purchase of intangible assets																					0	-17,886,000
payments made on capital lease obligations																					-41,000	-38,000	-49,000	-17,000	-41,000	-21,000	-23,000
net increase in cash and cash equivalents																					12,432,000	9,011,000
cash and cash equivalents—end of period
accrued expenses																						-660,000
other liabilities																						36,000
payment of offering costs related to initial public offering and follow-on offering																								-485,000
amortization of rou
unrealized translation (gains) losses on obligation related to royalty																										-144,000
non-cash interest expense																											-3,000
loss on debt extinguishment
long-term operating lease liabilities net of rou
payment related to settlement of debt and buyout of royalty obligations
proceeds from issuance of convertible preferred stock, net of issuance costs
repurchase of convertible preferred stock
cash, cash equivalents and restricted cash - beginning of period																							0	0	0	140,544,000
cash, cash equivalents and restricted cash - end of period																							-3,960,000	-27,465,000	20,864,000	153,789,000
capitalized license fees financed through future royalty payment
issuance of series d convertible preferred stock in exchange for a technology license agreement
increase in purchases of property and equipment included in accounts payable and accrued expenses
property and equipment acquired under capital leases
amortization of discounts on marketable securities																								-677,000	-723,000	-553,000
benefit from income taxes
purchases of intangible assets and capitalized license obligations
proceeds from follow-on offering, net of underwriting discounts and commissions																								0
deferred tax assets
business acquisitions, net of cash acquired
payment of offering costs related to initial public offering																										-89,000	-4,165,000
proceeds from initial public offering, net of underwriting discounts and commissions
unrealized translation losses on obligation related to royalty
amortization of premium or discounts on marketable securities

We provide you with 20 years of cash flow statements for Guardant Health stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Guardant Health stock. Explore the full financial landscape of Guardant Health stock with our expertly curated income statements.

The information provided in this report about Guardant Health stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.